REFERENCES
2. Bauer HC, Krizbai IA, Bauer H, Traweger A. “You Shall Not Pass”-tight junctions of the blood brain barrier. Front Neurosci 2014;8:392.
3. Vuillemenot BR, Kennedy D, Reed RP, et al. Recombinant human tripeptidyl peptidase-1 infusion to the monkey CNS: safety, pharmacokinetics, and distribution. Toxicol Appl Pharmacol 2014;277:49-57.
4. Kawasaki H, Kosugi I, Sakao-Suzuki M, Meguro S, Tsutsui Y, Iwashita T. Intracerebroventricular and intravascular injection of viral particles and fluorescent microbeads into the neonatal brain. J Vis Exp 2016; doi: 10.3791/54164.
5. Driesse MJ, Kros JM, Avezaat CJ, et al. Distribution of recombinant adenovirus in the cerebrospinal fluid of nonhuman primates. Hum Gene Ther 1999;10:2347-54.
6. Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol 2006;147 Suppl 1:S232-40.
7. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 2015;16:358-72.
8. Sankowski R, Mader S, Valdés-Ferrer SI. Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci 2015;9:28.
10. Galimberti D, Fenoglio C, Scarpini E. Inflammation in neurodegenerative disorders: friend or foe? Curr Aging Sci 2008;1:30-41.
11. Mitchell RM, Freeman WM, Randazzo WT, et al. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 2009;72:14-9.
12. Lindqvist D, Hall S, Surova Y, et al. Cerebrospinal fluid inflammatory markers in Parkinson’s disease - associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 2013;33:183-9.
13. Darweesh SKL, Wolters FJ, Ikram MA, de Wolf F, Bos D, Hofman A. Inflammatory markers and the risk of dementia and Alzheimer’s disease: a meta-analysis. Alzheimers Dement 2018;14:1450-9.
14. Zhai R, Rizak J, Zheng N, et al. Alzheimer’s Disease-like pathologies and cognitive impairments induced by formaldehyde in non-human primates. Curr Alzheimer Res 2018;15:1304-21.
15. Li H, Lei X, Huang B, et al. A quantitative approach to developing Parkinsonian monkeys (Macaca fascicularis) with intracerebroventricular 1-methyl-4-phenylpyridinium injections. J Neurosci Methods 2015;251:99-107.
16. Erratum: Forny-Germano et al. , “Alzheimer’s Disease-like pathology induced by amyloid-β oligomers in nonhuman primates”. J Neurosci 2020;40:8204.
17. Tate DF, Bigler ED. Fornix and hippocampal atrophy in traumatic brain injury. Learn Mem 2000;7:442-6.
18. Tomaiuolo F, Carlesimo GA, Di Paola M, et al. Gross morphology and morphometric sequelae in the hippocampus, fornix, and corpus callosum of patients with severe non-missile traumatic brain injury without macroscopically detectable lesions: a T1 weighted MRI study. J Neurol Neurosurg Psychiatry 2004;75:1314-22.
19. Tsai SY, Gildengers AG, Hsu JL, Chung KH, Chen PH, Huang YJ. Inflammation associated with volume reduction in the gray matter and hippocampus of older patients with bipolar disorder. J Affect Disord 2019;244:60-6.
20. Aziz N. Measurement of circulating cytokines and immune-activation markers by multiplex technology in the clinical setting: what are we really measuring? For Immunopathol Dis Therap 2015;6:19-22.
21. Koelman L, Pivovarova-Ramich O, Pfeiffer AFH, Grune T, Aleksandrova K. Cytokines for evaluation of chronic inflammatory status in ageing research: reliability and phenotypic characterisation. Immun Ageing 2019;16:11.
22. Belzeaux R, Lefebvre MN, Lazzari A, et al. How to: measuring blood cytokines in biological psychiatry using commercially available multiplex immunoassays. Psychoneuroendocrinology 2017;75:72-82.
23. McKay HS, Margolick JB, Martínez-Maza O, et al. Multiplex assay reliability and long-term intra-individual variation of serologic inflammatory biomarkers. Cytokine 2017;90:185-92.
